Commercialized Natural Biopolymeric Composites for Tissue Engineering and Drug Delivery

By utilizing the inherent biocompatibility, biodegradability, and functionalizability of polymers such as chitosan, alginate, collagen, gelatin, hyaluronic acid, dextran, silk, and cellulose derivatives, natural biopolymeric composites have quickly developed into clinically relevant platforms for tissue engineering and drug delivery. Patient-specific architectures with graded porosity, mechanical competence, and integrated drug reservoirs are made possible by recent advancements in multiscale fabrication, including electrospinning, freeze-drying, additive manufacturing, coaxial/triaxial fiber spinning, and green cross-linking. By combining structural support with biochemical and electromechanical cues, composites that combine natural matrices with inorganic fillers (nHA, β-TCP, bioactive glass), conductive nanofillers, or reinforcing fibers create scaffolds specifically designed for bone, skin, neural, cardiac, and cartilage repair in tissue engineering. Mucoadhesion, stimulus-responsiveness, targeted surface functionalization, and co-encapsulation techniques are used in drug delivery formats ranging from nanoparticles, microspheres, beads, and films to hydrogels, nanofibers, and coated tablets for improved bioavailability, localized release, and combination therapy (including anticancer regimens and extracellular vesicle delivery). There are still issues with batch variability, sterilization-compatible chemistries, scalable GMP manufacture, long-term mechanical durability, and rigorous in-vivo safety/efficacy data, but translation is strengthened when materials and procedures match current regulatory experience. The adoption of natural biopolymeric composites as next-generation commercial therapies will be accelerated by addressing these through standardized characterization, modular design, and clinician-focused manufacturing.